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1. Introduction
Mumps is an acute contagious disease which is endemic world-
wide [1]. Infection typically occurs in childhood, though it can also
occur in adults, among whom some complications can be more
frequent than among children. Infection, even if asymptomatic,
induces a long-lasting immunity [2].
The disease is usually benign, and 30% of paediatric cases are
asymptomatic. Severe complications, though rare, include hear-
ing loss in children (5/100,000) and encephalitis (incidence of
<2/100,000 cases, of which 1% are fatal). Adults have a greater
risk than children of meningo-encephalitis. When acquired after
puberty, mumps can be related to orchitis, testicular atrophy
and even sterility in males, and to mastitis and oophoritis in
females. Mumps infection in the first 12 weeks of pregnancy may
result in foetal loss [3]. Other important characteristics of mumps
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as been recommended for a number of years, vaccination coverage for
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iduals was higher than 20% in persons 2–14 years of age and exceeded
age. No statistically significant differences were observed by gender or
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are the occurrence of asymptomatic forms, the infectious period
preceding the possible clinical onset, and the lack of a specific
therapy.
The epidemiological impact of mumps and its possible seque-
lae have prompted the development of a vaccine, which currently
represents the best option for preventing the disease and its com-
plications.
The mumps vaccine contains live attenuated virus and is avail-
ableasa single-antigenpreparation, as a trivalent combinationwith
measles and rubella vaccines (MMR) [4], or as aquadrivalent combi-
nation with measles, rubella and varicella vaccines [5]. More than
10 different live attenuated viral strains are included in mumps
vaccines worldwide.
In Italy, for many years the Rubini strain has been widely used.
The poor effectiveness in preventing mumps of this strain and its
nationwide use has contributed to the failure of control of this dis-
ease in the 1990s [6]. In June 2001 the registration of the products
containing this specific vaccine strain was revoked [7] and since
then widely used live attenuated mumps vaccine strains in Italy
have included or include the Jeryl Lynn, Urabe and RIT4385 strains.
The adoption of a single dose schedule has led to a signifi-
cant decrease in the incidence of mumps, yet outbreaks continue
to occur in school settings [8–10]. A two-dose schedule is report-
edly even more effective in decreasing mumps incidence and has
allowed many countries to achieve near-elimination of the dis-
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ease, as defined by WHO (incidence <1 case/100,000 inhabitants)
[3,11,12].
In Italy there are some mandatory vaccinations (diphtheria,
tetanus, polio, and hepatitis B), but mumps is not.
In 1982, immunization began to be recommended for pre-
and post-pubertal susceptible males [13], and since 1999, a triva-
lent combined vaccine (MMR) has been available and actively
offered free of charge to all children in the second year of life [14].
The 2005–2007 National Vaccination Plan recommends using a
two-dose schedule [15]. Although vaccination coverage (VC) has
increased as a result of the use of the MMR vaccine, it is still sub-
optimal. The national mean VC in children 15–23 months of age
was estimated to be 56% in 1998 and 77% in 2002 [16,17].
The objective of the present study was to describe the epidemi-
ology of mumps in Italy using a number of data sources and to
determine whether or not there have been changes in seropreva-
lence by comparing the results of two studies conducted 8 years
apart.
2. Materials and methods
2.1. Incidence data
In Italy, mumps is subject to mandatory notification [18], and
all reported cases are recorded by Italy’s National Census Bureau
(ISTAT). The clinical case definition is sufficient for a case to be
reported; laboratory diagnosis is not required. The clinical case def-
inition is a mono or bi-lateral swelling of salivary glands (parotidis
or others glands) lasting at least 2 days and absent/moderate fever,
without other concomitant pathologies.
We calculated the incidence for the period 1991–2004 for the
entire country and for three main geographical areas (northern
Italy, central Italy, and southern Italy and the islands), based on
mandatory notifications, using as reference the Italian population
included in the national census (for the years 1991 and 2001)
or estimates provided by ISTAT (for the remaining years). We
also calculated the trend in incidence for the periods 1991–1995,
1996–2000 and 2001–2004, by age class: 0–14, 15–24, 25–64, and
≥65 years. For each of these periods, the trend in incidence by geo-
graphical area and the percentage of notifications in different age
groups were also determined.
2.2. Analysis of other databasesGiven that mandatory notification is affected by underreport-
ing, we analysed data from other databases with information on
mumps. In particular, we considered the incidence data for the
years 2000–2004 provided by Italy’s Paediatric Sentinel Surveil-
lance System of Vaccine-Preventable Diseases (SPES), a network
of paediatricians located throughout Italy and co-ordinated by the
Istituto Superiore di Sanita` (Italy’s National Health Institute). We
also examined theNational Hospital DischargeDatabase, created in
1994,which collects information on all hospitalisations recorded in
Italy [19]. For the analysis of this latter database, we considered the
main reason for hospitalization, which is codified using the ICD9-
CM code (0072 for mumps). The analysis was performed on data
for the period 1999–2004.
2.3. Seroprevalence study
A national cross-sectional population-based seroprevalence
study of mumps antibodies was performed on samples collected in
the period from January 2003 to October 2004 in each of Italy’s 19
Regions and 2 Autonomous Provinces. Assuming an overall mumps
prevalence of 70%, a sample size of 2017 sera was required to6 (2008) 2906–2911 2907
achieve 95% confidence intervals, with a precision of the estimate
of 2%. The samples, taken for diagnostic purposes or routine ascer-
tainment, had been frozen at −20 ◦C until use and were analysed
by the same national reference laboratory (University of Salento,
Lecce).
For each individual from whom blood had been collected, the
purpose of the study was explained and oral informed consent
was obtained. We excluded from the study immuno-compromised
patients, patients who had received a blood transfusion in the pre-
vious 6 months, and patients with an acute infectious disease.
Each Regional reference laboratory was asked to collect 6 sam-
ples for each year of age in the 0–20-year age group, 10 samples
for each 5-year range in the 21–40-year age group, and a total of
10 samples for the 41–50-year age group. The samples had to be
equally representative of males and females. Mumps antibodies
were quantified using an immunoenzyme micro-method (Enzyg-
nost Anti-Parotitis-Virus IgG, Dade Behring, GmbH), which has a
high sensitivity and specificity (95.4% and 93.7%, respectively) [20].
The following criteria were applied for the qualitative evalua-
tion:
IgG negative sample E<0.100 (cut-off)
IgG positive sample E>0.200
Equivocal IgG sample 0.100<E<0.200
The equivocal samples were retested: if the result was con-
firmed, the sample was classified as “equivocal”. The IgG positive
sampleswerequantitativelyevaluatedusing the following formula:
Log10 titer =˛×Eˇ, where ˛ and ˇ represent lot-dependent con-
stants. Antibody activity was expressed as titer.
2.4. Statistical analysis
The statistical analysis was performed using STATVIEW 5.1 for
Macintosh (Abacus Concepts, Inc., Berkeley, CA, 1992). Seropreva-
lence data were summarized as percentages, and positive antibody
titres were presented as geometric means. Differences between
percentages were assessed by the 2-test, whereas differences
between geometricmean titreswere assessed by Student’s t-test of
logarithmically transformed values. The datawere also analysed by
gender and geographical area andwere then comparedwith results
obtained from a seroprevalence study conducted in 1996 using the
same assay and cut-off [21].
3. Results3.1. Incidence data
Based on data provided by ISTAT, mumps was confirmed to
affect a large portion of the population and to be characterized by
an endemo-epidemic course, with outbreaks every 4–5 years. The
overall annual incidence ranged from125.1 to 4.5 cases per 100,000
population in the years 1991–2004 (Fig. 1).
For all three periods (1991–1995, 1996–2000 and 2001–2004)
and the different age groups (0–14, 15–24, 25–64 and >65 years), it
was clear that mumps mainly affects children (0–14 years). How-
ever, in this age group, the incidence progressively and significantly
decreased (p<0.01), from 409.2 cases per 100,000 population in
1991–1995, to 365.9 in 1996–2000 to 97.6 in 2001–2004. A similar
trend, with a significantly decreasing incidence, was found in the
other agegroupswhencomparingdifferentperiods (p<0.01, except
for persons older than 65 years of age when comparing 1996–2000
to 2001–2004, p<0.05).
When comparing persons 0–14 years of age to all older individ-
uals, the differences in the percentage of cases did not significantly
change over the three periods. The analysis by geographical area
showed that the trend in incidence was similar when comparing
2908 G. Gabutti et al. / Vaccine 26 (2008) 2906–2911
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Table 1
Incidence of mumps per 100,000 children 0–14 years, Italy, 2000–2004
Year Northern (Italy) Central (Italy) Southern (Italy) Italy000 1917 2274 1830 1939
2001 1518 665 761 1039
2002 302 206 150 220
2003 215 81 116 149
2004 109 65 54 79
Data from paediatric sentinel surveillance (SPES).
the three areas and that there was a clear north–south gradient,
with the highest incidence consistently found for northern Italy,
followed by central and southern Italy (Fig. 1).
3.2. Analysis of other databases
In the period 2000–2004, 11,697 cases of mumpswere reported
to SPES, with the annual incidence progressively decreasing from
1939 per 100,000 children (0–14 years) (2000) to 79 per 100,000
children (2004). In general, incidence rateswere higher in northern
and central Italy than in southern Italy (Table 1).
According to the National Hospital Discharge Database, in the
period 1999–2004 there was an annual mean of 363 hospitaliza-
Figure 2. Mumps seroprevalence by age group and ged 2004 (total and by geographic areas) (Italy’s National Census Bureau, ISTAT).
tions and 247-day-hospital admissions for mumps, with a peak in
2000 (619 and 325 hospitalizations and day-hospital admissions,
respectively). The mean duration of stay was 2.54 days.3.3. Seroprevalence study
Overall, 3094 blood sampleswere analysed; 2276were positive,
621 were negative, and 197 were equivocal. The seroprevalence
showed a typical pattern. In the first year of life (when children
are passively protected by the mother), 25.4% of individuals 0–11
months oldwere seropositive; among 12–23-month olds, the sero-
prevalencewas30.8% (differencenot significant). For 2–4-year olds,
the seroprevalence significantly increased (64.4%, p<0.01 com-
pared to 12–23-month olds); it continued to increase with age,
though not always significantly: 65.0%, 78.9%, 83.5%, 89.2% and
92.8%, respectively, for the age classes 5–9, 10–14, 15–19, 20–39
and >40 years (Fig. 2). Of note was the finding that the percentage
of seronegative individuals was greater than 20% in the age groups
2–4, 5–9 and 10–14 years and greater than 10% in the age classes
15–19 and 20–39 years.
No statistically significant difference was found in seropreva-
lence when comparing males and females (Fig. 2). The trend in
seroprevalence was basically uniform when comparing the three
geographic areas, with no significant differences (Fig. 3).
nder in Italy (2004). 2-test: *p<0.05; **p<0.01.
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Figure 3. Mumps seroprevalence by geographical area in Italy (2004).
nce byFigure 4. Comparison between mumps seroprevale
The GMT progressively increased up to 10–14 years and then
significantly (p<0.01) decreased in the age class 15–19 years. There
werenosignificantdifferenceswhencomparingmales and females,
except for the age group 15–19 years (p<0.01).
3.4. Comparison of seroprevalence data from 1996 and 2004
Only in the age group 2–4 years was the seroprevalence in the
survey conducted in 2004 statistically higher than that in 1996
(p<0.01). No significant differences were detected in other age
classes (Fig. 4).
4. Discussion
Before vaccination was introduced, mumps was a common
infectious disease in all parts of the world, with the highest annual
incidence among 5–9-year olds. In many countries, the availabil-
ity of safe and efficacious vaccines has led to a rapid decrease in
morbidity. According to WHO, in 2004, mumps vaccination was
included in the vaccine schedules of 109 countries, which consti-
tutes a marked increase with respect to the 74 countries in 1999.
In 2004, a two-dose vaccination schedule, mainly with the MMR
vaccine, was extensively adopted (in 82% of the 109 countries) [22].age-group, Italy 1996 and 2004. 2-test: **p<0.01.
In countrieswhere itwaspossible to implement vaccination and
to rapidly achieve andmaintainhighVC, therehas beena consistent
decrease in morbidity [3].In Italy, mumps vaccination was introduced in the beginning
of 1980s and in 1982 the Ministry of Health recommended vac-
cination of susceptible males, both in pre- and post-puberty. The
availability of combined MMR vaccines permitted to start the
immunization of both males and females in the second year of life
and MMR vaccination has been included in the national vaccine
schedule since the beginning of 1990s. At that time the vaccines
commercially available contained at least 5000 TCID50 of one
of the following mumps strains: Jeryl Lynn, Urabe and Rubini.
The impact of vaccination on mumps was inadequate; notifica-
tions changed from 62,000 per year in the period 1980–1989
to 45,000 in the period 1990–1997. Epidemic peaks were regis-
tered every 3–4 years and over 80% of cases involved children
up to 15 years of age. During 1990s the observation of mumps
cases in already vaccinated subjects prompted even in Italy some
studies on the efficacy of commercially available vaccines; the
result was that the Rubini strain had a very low efficacy level
(23–31%) and that its wide use could be related to the unsatisfac-
tory control of mumps at national level [23–25]. For these reasons,
in July 2001 products containing Rubini strain were withdrawn
[7].
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In 2002, MMR vaccination, previously included in the national
vaccination schedule in 1999 [14] with the recommendation of
administering the first dose to children between 12 and 15 months
of age, and a second dose at 5–6 or 11–12 years of age, was included
among the vaccinations that each region must provide free-of-
charge to all children [26]. This decision has played an important
role in improving MMR vaccination coverage, especially in the
southwhere, according to 1998 EPI survey, one of themain reasons
reported by parents for not vaccinating their children was related
to the fact that the vaccine was not provided free of charge [27].
A second cluster sampling survey conducted in 2003, by using
the same method of the previous survey, revealed a vaccination
coverage rate of 77%, in the same age group [27].
This increase was confirmed by routinely collected data on VC
(from 85.7% in 2004 to 87.3% in 2005), as a result of the activities
required by the national plan for the elimination of measles and
congenital rubella through vaccination with the combined MMR
vaccine [28].
However, VC is still not sufficient because the control and/or
elimination/eradication of an infectious disease can only be
achieved by reaching and maintaining a 95% VC [4], so as to avoid
undesired effects, such as new cohorts of susceptible individuals,
an increase in the mean age of acquisition of the infection, and the
broadeningof the inter-epidemicperiod. The commitmentmadeby
Italy to eliminate measles and congenital rubella (<1 case/100,000
newborns) by 2010 [29] will also allow Italy to reach the targets
established for mumps for the WHO European Region, which have
been endorsed in the 2003–2005 National Health Plan and the
2005–2007 National Vaccine Plan [15,30,31].
In Italy, mumps incidence remained almost unchanged until
2001 (range: 25.9–125.1/100,000 inhabitants) and outbreaks were
reported every 2–4 years. Since 2002, notifications have rapidly
decreased, and in 2004 the lowest number of cases (2,604) was
reported (incidenceof 4.5/100,000 inhabitants). In the sameperiod,
data collected by the Istituto Superiore di Sanita` through the SPES
sentinel network confirmed this trend yet highlighted that the rou-
tine notification system suffers from remarkable underreporting.
Concerning this last point, it should be stressed theneed for a better
case definition for surveillance as mumps symptoms can be eas-
ily misinterpreted if not associated to an outbreak. Noteworthy,
when the incidence of mumps decreases, laboratory confirma-
tion should be necessary. Nonetheless, recent epidemiological data
show a decrease in mumps cases yet not an increase in the mean
ageof acquisitionof infection, as already reported inother countries
[32–35].
Comparison of seroprevalence data from1996 and2004 showed
a statistically significant increase in seroprevalence only in the age
class 2–4 years (41.2% vs. 64.4% in 1996 and2004, respectively) [21].
This seems to be the result of the latest immunization campaigns;
the efforts recently sustained in order to address the national
plan for the elimination of measles and congenital rubella through
vaccination have had a significant impact on seroprevalence
data.
Of note is the finding that in this age class, as well as in the
5–9- and 10–14-year age classes, more than 20% of children were
seronegative, and more than 10% of individuals 15–39 years of age
were susceptible.
These results demonstrate that VC in Italy is still sub-optimal
and that there exists a risk of outbreaks. The lack of adequate vac-
cine data processing management in some Regions and the high
rate of parents (18%) who intend to vaccinate their children at an
older age [17] could explain these observations and represent a
critical point in planning further priority activities.
In conclusion, this research highlights that vaccination strate-
gies and programmes should be further strengthened if the targets
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against mumps are to be attained. Surveillance systems and sero-
prevalence studies can be very important for the prevention and
control of infectious diseases, enabling the evaluation of the impact
of the interventions adopted.
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